Berlin-based digital therapeutics company, Dopavision has announced the closing of a €12 million Series A financing round to develop its lead product for childhood myopia.
Seventure Partners led the round and was joined by Novartis Pharmaceuticals and the company's existing shareholders, Boehringer Ingelheim Venture Fund and Ababax Health.
WHY IT MATTERS
Myopia is the leading cause of correctable...
